Technical Analysis for FUSN - Fusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 13.13 -3.67% -0.50
FUSN closed down 3.67 percent on Wednesday, August 5, 2020, on 16 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A N/A Down
Historical FUSN trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -3.67%
Hot IPO Pullback Bullish Swing Setup -3.67%
Narrow Range Bar Range Contraction -3.67%
Inside Day Range Contraction -3.67%
Wide Bands Range Expansion -3.67%
Bearish Engulfing Bearish -0.23%
New Downtrend Bearish -0.23%
1,2,3 Retracement Bearish Bearish Swing Setup -0.23%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Solid Tumors Antibodies Cell Biology Tumors Tyrosine Kinase Receptors Proteins Radiopharmaceuticals Pharmacodynamics Fibroblast Growth Factor Growth Factor

Is FUSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.0
52 Week Low 12.19
Average Volume 287,177
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 14.78
10-Day Moving Average 13.51
Average True Range 1.13
ADX 67.72
+DI 8.29
-DI 21.29
Chandelier Exit (Long, 3 ATRs ) 14.10
Chandelier Exit (Short, 3 ATRs ) 15.59
Upper Bollinger Band 17.60
Lower Bollinger Band 11.95
Percent B (%b) 0.21
BandWidth 38.27
MACD Line -1.23
MACD Signal Line -1.10
MACD Histogram -0.1331
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.41
Resistance 3 (R3) 14.55 14.26 14.19
Resistance 2 (R2) 14.26 13.94 14.19 14.12
Resistance 1 (R1) 13.70 13.74 13.56 13.56 14.05
Pivot Point 13.41 13.41 13.34 13.34 13.41
Support 1 (S1) 12.85 13.09 12.71 12.71 12.21
Support 2 (S2) 12.56 12.89 12.49 12.14
Support 3 (S3) 12.00 12.56 12.07
Support 4 (S4) 11.86